Matches in Wikidata for { <http://www.wikidata.org/entity/Q91576647> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q91576647 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q91576647 description "scientific article published on 22 July 2019" @default.
- Q91576647 description "wetenschappelijk artikel" @default.
- Q91576647 description "наукова стаття, опублікована 22 липня 2019" @default.
- Q91576647 name "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 name "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 type Item @default.
- Q91576647 label "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 label "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 prefLabel "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 prefLabel "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 P1433 Q91576647-F81E06CD-D753-4D23-A65C-FF7FAFB38D24 @default.
- Q91576647 P1476 Q91576647-B352DA50-8E38-40FD-BA60-4AF1445A4DB0 @default.
- Q91576647 P2093 Q91576647-02F038B6-96D1-4A3E-9132-8A664FC0201B @default.
- Q91576647 P2093 Q91576647-0CDAFE36-97B8-49BF-833A-2C5F76E37FA0 @default.
- Q91576647 P2093 Q91576647-10D7B274-CD26-4859-A1E7-C525C4591116 @default.
- Q91576647 P2093 Q91576647-6EA0F2FD-BD88-4964-889C-D501E628971F @default.
- Q91576647 P2093 Q91576647-6FA61642-0CC2-47A8-AEB1-D08747CCECD7 @default.
- Q91576647 P2093 Q91576647-7FA1C58B-EBB2-46BC-A6B7-769286A1068B @default.
- Q91576647 P2093 Q91576647-881A4D83-1906-466F-ADDC-F2B3585AA403 @default.
- Q91576647 P2093 Q91576647-97EBDE41-74DD-4237-92EF-B90DD340A4AD @default.
- Q91576647 P2093 Q91576647-B8BB9DEB-01C4-464F-95AD-1C9D23418585 @default.
- Q91576647 P304 Q91576647-C668D054-6291-4D39-A4D5-5B1FFC5534A5 @default.
- Q91576647 P31 Q91576647-D1694517-FCD7-4FB8-A268-60F86146E63D @default.
- Q91576647 P356 Q91576647-70D5CA62-D8E4-45A1-929E-E823748BEAAB @default.
- Q91576647 P50 Q91576647-2E6AE5F0-2BF3-4F01-A289-21763F867ABC @default.
- Q91576647 P577 Q91576647-9D561954-2537-4C8F-89C8-53173359360E @default.
- Q91576647 P698 Q91576647-6F759742-A2D2-43C1-8BA4-A91F2E024AFC @default.
- Q91576647 P921 Q91576647-8B168654-A362-4DC5-9A96-115D4B9BA2E9 @default.
- Q91576647 P356 09546634.2019.1640348 @default.
- Q91576647 P698 31268369 @default.
- Q91576647 P1433 Q6295084 @default.
- Q91576647 P1476 "Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis" @default.
- Q91576647 P2093 "Alan M Mendelsohn" @default.
- Q91576647 P2093 "Boni Elewski" @default.
- Q91576647 P2093 "Jeffrey Crowley" @default.
- Q91576647 P2093 "Jeffrey Parno" @default.
- Q91576647 P2093 "Kenneth Gordon" @default.
- Q91576647 P2093 "Simon Lowry" @default.
- Q91576647 P2093 "Stephen Rozzo" @default.
- Q91576647 P2093 "Stephen Tyring" @default.
- Q91576647 P2093 "Yang Zhao" @default.
- Q91576647 P304 "1-6" @default.
- Q91576647 P31 Q13442814 @default.
- Q91576647 P356 "10.1080/09546634.2019.1640348" @default.
- Q91576647 P50 Q88232970 @default.
- Q91576647 P577 "2019-07-22T00:00:00Z" @default.
- Q91576647 P698 "31268369" @default.
- Q91576647 P921 Q10355321 @default.